Previously, several studies have been reported that FH is frequently mutated in renal cancer [48], ELOVL2 is upregulated in hepatocellular cancer [49], and ACADL is associated with prostate cancer progression[45]. This evidence concerns the gene ACADL and prostate carcinoma.